• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Cancer

Dana-Farber Cancer Institute patents new IRAK-4 inhibitors

Feb. 6, 2024
Research at Dana-Farber Cancer Institute Inc. has led to the identification of new interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Read More
Brain, illustrating pain/injury
Neurology/Psychiatric

New pediatric rat model of DFP-induced status epilepticus

Feb. 6, 2024
Researchers from Texas A&M University System have detailed the development and characterization of a novel pediatric rat model of organophosphate (OP)-induced status epilepticus (SE).
Read More
Illustration of chronic lymphocytic leukemia cells
Cancer

Imipridone analogue effective alone and with venetoclax in vitro against CLL

Feb. 6, 2024
Increasing knowledge on chronic lymphocytic leukemia (CLL) proliferation processes suggests that targeting not only leukemic cells but also the tumor microenvironment (TME) and their interactions across drug combination strategies may lead to advances in this complex setting.
Read More
Test tube, dropper
Dermatologic

Fermion’s TYK2 JH2 inhibitor cleared by China NMPA to advance into clinic

Feb. 6, 2024
Guangzhou Fermion Technology Co. Ltd. has received IND approval by China’s National Medical Products Administration (NMPA) for its TYK2 JH2 inhibitor, FZ-007-119.
Read More
Vial and syringe with DNA
Immune

Multivalent antigen display using DNA origami scaffolds boosts targeted antibody responses

Feb. 6, 2024
Protein-based virus-like particles (P-VLPs) have emerged as a promising platform for multivalent subunit vaccines.
Read More
Cancer

DNMT3L overexpression abrogates HCC proliferation, study unveils

Feb. 6, 2024
Hepatocellular carcinoma (HCC) remains among the most aggressive tumor types and its early diagnosis is still a challenge.
Read More
Art concept for gene therapy research
Neurology/Psychiatric

Encoded Therapeutics’ gene therapy for SCN1A+ Dravet syndrome gets clinical green light in US and Australia

Feb. 6, 2024
Encoded Therapeutics Inc. is advancing its lead gene therapy candidate, ETX-101, for the treatment of SCN1A+ Dravet syndrome into the clinic.
Read More
Blood glucose chart and monitor, stethoscope, injector pen
Endocrine/Metabolic

First demonstration of systemic treatment to prevent diabetes complications

Feb. 6, 2024
Diabetic retinopathy and diabetic kidney disease are frequent microvascular complications of diabetes, both related to exacerbated vascular permeability coming from microvascular barrier malfunctioning.
Read More
Immuno-oncology

Targeting RNase1 reduces resistance to anti-PD-1 immunotherapy in HCC

Feb. 6, 2024
Researchers from Sun Yat-Sen University and MD Anderson Cancer Center have compared the proteins secreted by hepatocellular carcinoma (HCC) cells in responders and nonresponders to the anti-PD-1 antibody nivolumab.
Read More
Artwork depicts KIBRA-dependent recovery of functional plasticity at synapses despite tau-induced toxicity in the brain.
Neurology/Psychiatric

KIBRA restores tau-driven damage in Alzheimer’s disease

Feb. 6, 2024
By Xavier Bofill Bruna
It is well known that protein tau forms aggregates in the brain in neurodegenerative diseases such as Alzheimer’s disease (AD) that are also known as tauopathies. Accumulation of protein tau in the brain leads to the cell toxicity and promotes the loss of synaptic plasticity, which in turn causes memory loss. As reported on Feb. 1, 2024, in The Journal of Clinical Investigation, assistant professor Tara Tracy and her research team from the Buck Institute for Research on Aging have discovered a protein in the brain that could restore this damage induced by protein tau.
Read More
Previous 1 2 … 522 523 524 525 526 527 528 529 530 … 17774 17775 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe